Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas

BACKGROUND: Trabectedin has recently been approved in the USA and in Europe for advanced soft-tissue sarcoma patients who have been treated with anthracycline-based chemotherapy without success. The mechanism of action of trabectedin depends on the status of both the nucleotide excision repair (NER)...

Descripción completa

Detalles Bibliográficos
Autores principales: Laroche, Audrey, Chaire, Vanessa, Le Loarer, François, Algéo, Marie-Paule, Rey, Christophe, Tran, Kevin, Lucchesi, Carlo, Italiano, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5387279/
https://www.ncbi.nlm.nih.gov/pubmed/28399901
http://dx.doi.org/10.1186/s13045-017-0451-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5387279/
https://www.ncbi.nlm.nih.gov/pubmed/28399901
http://dx.doi.org/10.1186/s13045-017-0451-x

Ejemplares similares